SECsense Logo

Eupraxia Pharmaceuticals Inc. Reports Form 6-K for February 2025 Filing

$EPRX
Form 6-K
Filed on: 2025-02-18
Source
Eupraxia Pharmaceuticals Inc. Reports Form 6-K for February 2025 Filing

Here are the key insights extracted from the provided section of the financial report (Form 6-K) for Eupraxia Pharmaceuticals Inc.:

  1. Report Type and Filing Date:
  • This is a Form 6-K report filed by a foreign private issuer.
  • The report is for the month of February 2025.
  1. Company Information:
  • Name: Eupraxia Pharmaceuticals Inc.
  • Location: 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
  • Contact: Telephone number is (250) 590-3968.
  1. SEC Commission File Number: 001-41923
  2. Annual Report Filing Indication:
  • The registrant indicates that it files annual reports under Form 40-F.
  1. Included Documents:
  • The report includes a press release dated February 18, 2025, referenced as Exhibit 99.1.
  1. Signatures:
  • The report is signed by Alex Rothwell, who is the Chief Financial Officer of Eupraxia Pharmaceuticals Inc.
  • The signature is dated February 18, 2025.

Summary:

This document is a regulatory filing indicating that Eupraxia Pharmaceuticals Inc. has submitted a Form 6-K to the SEC for February 2025. The filing includes details about the company's identity, its SEC file number, and a confirmation of its filing status regarding annual reports. It also mentions a press release that is part of this filing. The report is officially signed by the CFO, validating its contents.